Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Bordeaux
About this trial
Glioblastomas are the most frequent and aggressive malignant tumors of the CNS in adults, with almost systematic relapse despite treatment with surgery followed by radio-chemotherapy (STUPP protocol). The aim of this study is to better characterize transcriptomic, proteomic and metabolic changes in relapsed glioblastoma compared to the initial tumor, in order to identify new prognostic markers and potential new therapeutic targets.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
age > 18 years
surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux
Disqualifiers
systemic therapy received for non-glioblastoma tumor
Trial population
Patients with relapsed glioblastomas reoperated at the University Hospital of Bordeaux, France, between 2005 and 2023, for which tumor material is available
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Relapsed glioblastoma
Biological/VaccinePaired tumor samples diagnosis/relapse
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: Patients operated for primary and recurrent glioblastoma1 intervention
Trial outcomes
Primary outcomes
1
Evaluation of metabolic changes involved in glioblastoma relapse
Relative abondance of metabolite and differential enzyme expression in a recurrence versus primary sample
Time frame
Up to 2 years after the start of the studySecondary outcomes
1
Progression-free survival
Progression-free survival of patients who underwent surgery for relapse glioblastoma after the surgery of relapse measured at time of inclusion
Time frame
From date of the second surgery until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years2
Overall survival
Overall survival of patients who underwent surgery for relapse glioblastoma after the surgery of relapse
Time frame
From date of the second surgery until the date of death from any cause, assessed up to 5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov